The Conversation
Academic rigour, journalistic flair
Arts + Culture
Business + Economy
Education
Environment + Energy
Health + Medicine
Politics + Society
Science + Technology
In French
How changing drug patent rules will affect developing nations
November 21, 2016 10.53pm SAST
By Natalie Schellack - Associate Professor and Course Leader: Post Graduate Programmes in Clinical Pharmacy in the Department of Pharmacy, Sefako Makgatho Health Sciences University
Disclosure statement
Natalie Schellack does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond the academic appointment above.
Partners
The Conversation is funded by Barclays Africa and seven universities, including the Cape Peninsula University of Technology, Rhodes University and the Universities of Cape Town, Johannesburg, Kwa-Zulu Natal, Pretoria, and South Africa. It is hosted by the Universities of the Witwatersrand and Western Cape, the African Population and Health Research Centre and the Nigerian Academy of Science. The Bill & Melinda Gates Foundation is a Strategic Partner. more
Republish this article
Republish
Republish our articles for free, online or in print, under Creative Commons licence.
Only by importing and manufacturing generic drugs can developing nations afford to meet their people’s health care needs. Mohamed Abd El Ghany/Reuters
Email
Twitter51
Facebook41
LinkedIn
Print
After years of legal battles, a global agreement has been reached for developing countries to buy – and for drug manufacturers to produce or import – generic medicines without breaching patent rules. The Conversation Africa’s Health and Medicine Editor Candice Bailey asked Natalie Schellack to explain what this means for the developing world.
Are drugs about to become cheaper for poor people in developing countries? Why?
Through the World Trade Organisation an agreement was reached in November 2015 for the world’s poorest countries to buy –- and for drug manufacturers to produce or import –- generic medicines without breaching patent rules until January 1 2033. The decision was taken by the organisation’s Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS).
Put simply, the need of a nation trumped the right to derive protected benefit from a patent. This initiative will help developing countries come up with better policies. It will provide legal certainty, which should lead to better access and more affordable drug prices.
The agreement is good news for all countries in the Southern African Development Community as members of the World Trade Organisation (with the exception of the Seychelles). They’ll be able to incorporate the TRIPS agreement into their national laws. The community’s protocol on Trade confirms this position.
South Africa, as a signatory to the TRIPS agreement, is allowed to pass intellectual property legislation, inclusive of patent laws, so that intellectual property rights do not become barriers to legitimate trade while ensuring the technology is transferred and disseminated in line with social and economic welfare.
If South Africa actively participates in this opportunity for more generic trade, medicines should be more affordable.
South Africa has been fighting for access to generic drugs for some time. In the late 1990s around 40 big pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim filed a lawsuit to the Pretoria High Court against the South African government due to the importation of generic anti-retroviral medicine to treat the HIV/AIDS pandemic.
Millions of people were suffering from HIV/AIDS and could not afford the original brand-name medicines. The South African state was trying to find a way to guarantee their health. After three years the court overruled the patent law in this case and recognised the right to health as a basic human right of South African patients.
How do patents affect prices?
A patent in this context is when a pharmaceutical company develops a new drug for a disease. The company sells it under a “brand name”. The patent protects the pharmaceutical company’s right to manufacture and market the drug to profit from it. This helps recover the costs that have gone into developing the drug.
In most cases the drug patent is awarded for around 20 years. Once the patent has expired other companies can “copy” and manufacture the drug.
Generic drugs have to be near-identical “copies” of the branded drug. For example, they must be identical– or “bioequivalent”–to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. In South Africa this is regulated by the Medicine Control Council of South Africa.
For a developing country like South Africa, the most effective and sustainable way to bring down the price of a drug is by driving competition between different generic manufacturers. This can’t be done if a medicine is still under patent and the patent owner is not willing to allow competition. Preventing competition can drive up the price to an artificially high level.
Developing countries can’t afford this. Life-saving treatments for diseases such as HIV/AIDS, tuberculosis and malaria are needed. The price of medicine for people with these diseases is a matter of life or death.
What changes and challenges has South Africa made to patent laws and how could they affect people?
South Africa’s draft Intellectual Property Protection Policy of 2013 is designed to reform the country’s patent law and to address various shortcomings that hamper access to medicine. The draft policy provides public health safeguards and promotes cooperation between ministries. And more recently, South Africa’s cabinet approved a new Intellectual Property framework.
The three-year delay in finalising the policy first set out in 2013 has affected the health of certain patients adversely. Two examples stand out. Patients with multidrug-resistant tuberculosis (MDR-TB) struggle to pay for one of the medications they need called linezolid. The hepatitis B medication, entecavir, is another example. It remains inaccessible to most people because it’s so expensive – while generic products are available outside South Africa at prices that are around 84% lower.
Once the policy becomes law, South Africa could be a role model for the rest of the world in prioritising people’s health over profit.
What more needs to be done?
The process of finalising the Intellectual Property Protection Policy needs to be treated with urgency. The Department of Trade and Industry and all ministries involved must continue to prioritise turning it into law.
This will mean more affordable medicines can become available.
But there are other steps that can be taken too.
The most effective and sustainable way to bring down the price of a drug is through competition between manufacturers.
Investment is also needed. This can be promoted by having large pharmaceutical companies invest directly in South Africa to boost local production of medicines. And the approval process for new medicines should be streamlined by the Medicine Control Council.
Another market in South Africa that should get more attention is clinical trial research. This would not only allow research into conditions inherent to South Africa, it would also be an investment in local specialists.
The distribution of medicines throughout South Africa by the National Department of Health should be streamlined to avoid medicines being unavailable. One solution could be to transfer logistical and distribution costs of medicines to the suppliers to avoid delays, additional transport costs and stock-outs.
Patent law
Intellectual property
TRIPS
GlaxoSmithKline
World Trade Organisation
SADC
Southern African Development Community
Tweet
Share
Get newsletter
You might also like
India’s Novartis patent ruling puts health before profits
World’s poorest countries allowed to keep copying patent-protected drugs
Trade talks set to undermine access to medicines for the world’s poor
Explainer: the problem drug patents pose for developing countries
Sign in to comment
1 Comment
Oldest Newest
Jerzy Zbyslaw
Regarding
“South Africa has been fighting for access to generic drugs for some time. In the late 1990s around 40 big pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim filed a lawsuit to the Pretoria High Court against the South African government due to the importation of generic anti-retroviral medicine to treat the HIV/AIDS pandemic.Millions of people were suffering from HIV/AIDS and could not afford the original brand-name medicines.”
and
“Developing countries can’t afford this. Life-saving treatments for diseases such as HIV/AIDS, tuberculosis and malaria are needed. The price of medicine for people with these diseases is a matter of life or death.”
I think this may be a big problem in the future as I read somewhere (could still fall within the realms of science fiction today however) that pharmaceutical companies want to manufacture drug biologicals that are keyed to the DNA of the recipient and hence completely useless to anyone else, therefore if you can pay ($$$) for the cure you will get it and if you can’t then your on your own as copying someone else’s medicine won’t achieve anything which is exactly what those companies want.
Read more
10 months ago
Report
Most popular on The Conversation
The Moringa tree enters the arsenal of treatments against chronic diseases
Why, a decade on, a new book on Zuma’s rape trial has finally hit home
Sixty years after Sputnik: taking stock and looking to the future
The way French is taught in South Africa offers lessons in decolonisation
Shale gas in South Africa: game-changer or damp squib?
What Archbishop Tutu’s ubuntu credo teaches the world about justice and harmony
Why you shouldn’t wrap your food in aluminium foil before cooking it
Why the dream of a prosperous, united nation continues to elude South Africa
Why hunger is on the rise in the world, and what can be done about it
Conservation efforts can’t afford to shy away from high-risk conflict zones
Expert Database
Find experts with knowledge in:*
Want to write?
Write an article and join a growing community of more than 57,000 academics and researchers from 2,176 institutions.
Register now
The Conversation
Community
Community standards
Republishing guidelines
Research and Expert Database
Analytics
Job Board
Our feeds
Company
Who we are
Our charter
Our team
Partners and funders
Contributing institutions
Resource for media
Contact us
Stay informed
Subscribe to our Newsletters
Follow us on social media
Privacy policy Terms and conditions Corrections
Copyright © 2010–2017, The Conversation Africa, Inc.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment